Zymeworks (ZYME)

Company Profile

Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other diseases. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers. Zymeworks’ next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibody therapeutics (MSAT). In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Company profile

Ticker

ZYME

Exchange

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Zymeworks Delaware Inc.

SEC CIK

0001937653

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Analyst ratings and price targets

Last 3 months

Average target

$9.50

Low target

$8.00

High target

$11.00

Latest filings (excl ownership)

View all

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

4 Jan 23

8-K

Departure of Directors or Certain Officers

30 Dec 22

8-K

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

21 Dec 22

8-K

Submission of Matters to a Vote of Security Holders

19 Dec 22

8-K

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

19 Dec 22

CERT

Certification of approval for exchange listing

15 Dec 22

Voluntary exchange delisting

15 Dec 22

8-A12B

Registration of securities on exchange

15 Dec 22

8-K

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

9 Dec 22

Transcripts

ZYME

Earnings call transcript

2022 Q3

9 Nov 22

Latest ownership filings

View all

Change in insider ownership

23 Jan 23

Change in insider ownership

18 Jan 23

Change in insider ownership

BIOTECHNOLOGY VALUE FUND L P

Financial summary

Financial statements Chart ZYME financial data

Quarter (USD)	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)			96.08 mm
Cash burn (monthly)			16.79 mm
Cash used (since last report)			69.29 mm
Cash remaining			26.79 mm
Runway (months of cash)			1.6

Beta Read what these cash burn values mean

Financial data from Zymeworks earnings reports.

Institutional ownership, Q3 2022

ZYME institutional ownership history Ownership history

0.1% owned by funds/institutions

13F holders	Current	Change
Total holders	1	NEW
Opened positions	1	NEW
Closed positions	0
Increased positions	0
Reduced positions	0

13F shares	Current	Prev Q	Change
Total value	482.00 k	0.00	NEW
Total shares	78.39 k	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Kennedy Capital Management	78.39 k	$482.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Kennedy Capital Management	78.39 k	+78.39 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ZYME insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	9.8843	163,400	1.62 mm	9,887,473
19 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	9.4909	144,100	1.37 mm	9,724,073
18 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	9.9953	203,000	2.03 mm	9,579,973
17 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	9.8042	440,000	4.31 mm	9,376,973
13 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	9.806	342,100	3.35 mm	8,936,973
11 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	7.8731	106,300	836.91 k	8,594,873
10 Jan 23	EcoR1 Capital	Common Stock	Buy	Acquire P	Yes	No	7.6491	920,000	7.04 mm	8,488,573
5 Jan 23	Klompas Neil A	RSU Common Stock	Grant	Acquire A	No	No	0	58,500	0.00	58,500
5 Jan 23	Klompas Neil A	Stock Option Common Stock	Grant	Acquire A	No	No	8	87,500	700.00 k	87,500
5 Jan 23	Christopher Astle	RSU Common Stock	Grant	Acquire A	No	No	0	31,500	0.00	31,500